Dayvigo Cannabis Interaction Profile: What You Need to Know Before Combining Lemborexant and Cannabis

What Is Lemborexant and How Does It Work?

Lemborexant (brand name Dayvigo) is a dual orexin receptor antagonist approved by the FDA in December 2019 for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults [1]. Unlike older sedative-hypnotics such as benzodiazepines or Z-drugs, lemborexant does not cause broad GABAergic CNS depression. Instead, it selectively blocks orexin-1 (OX1R) and orexin-2 (OX2R) receptors, blunting the wake-promoting signaling that orexin neuropeptides produce [2].

That mechanistic difference is worth understanding before discussing cannabis. Because lemborexant is not a GABA agonist, it does not share the full sedative profile of diazepam or zolpidem. Yet the downstream result, a reduction in arousal state, is sedation by another pathway, and any additional CNS depressant layered on top compounds that effect.

FDA Approval and Labeled Doses

The FDA approved two doses: 5 mg and 10 mg, taken orally no more than once per night and within 30 minutes of intended sleep, with at least 7 hours remaining before the planned wake time [1]. The agency placed a Schedule IV controlled-substance classification on lemborexant, signaling abuse potential and CNS activity even at therapeutic doses.

Pharmacokinetic Basics

Lemborexant reaches peak plasma concentration (Tmax) in roughly 1 to 3 hours under fasted conditions. Its half-life is approximately 17 to 19 hours, meaning the drug is still present in measurable amounts the morning after a bedtime dose [1]. Hepatic metabolism through CYP3A4 is the primary clearance route; CYP3A5 contributes a minor fraction. This long half-life and CYP3A4 dependence are central to understanding why cannabis creates a two-pronged interaction problem.

How Cannabis Interacts With Dayvigo

Cannabis interacts with lemborexant through at least two distinct mechanisms: direct pharmacodynamic CNS depression and pharmacokinetic interference with CYP3A4 metabolism [3].

Pharmacodynamic Mechanism: Additive CNS Depression

THC (delta-9-tetrahydrocannabinol) binds CB1 receptors concentrated in cortical, hippocampal, and cerebellar regions, producing dose-dependent sedation, psychomotor slowing, and impaired executive function [4]. Lemborexant independently suppresses orexin-mediated arousal. When both are present, the sedative effects add together even though the receptor targets differ.

The FDA label for Dayvigo states explicitly: "Avoid use of DAYVIGO with other CNS depressants because of the risk of additive CNS depressant effects" [1]. Cannabis is listed in the label's CNS depressant category. This is not a theoretical concern. Driving-simulation studies of lemborexant 10 mg showed statistically significant impairment at 9 hours post-dose in healthy volunteers compared to placebo [5]. Adding THC to that residual drug exposure extends the impairment window and may worsen its depth.

Pharmacokinetic Mechanism: CYP3A4 Inhibition by CBD

Cannabidiol (CBD), the second major cannabinoid in most cannabis products, is a moderate inhibitor of CYP3A4 [3]. Because CYP3A4 is lemborexant's principal metabolic route, co-administration of CBD-containing cannabis may reduce clearance of lemborexant, raising its area under the curve (AUC) and prolonging sedation.

The magnitude of that CYP3A4 effect depends on:

• The CBD content of the specific cannabis product used
• Whether cannabis is smoked (faster absorption, shorter peak) or ingested as an edible (delayed but larger and more prolonged CBD plasma levels)
• Frequency of use, since chronic CBD use produces a more stable CYP3A4 inhibitory state than single-use administration

A 2020 review in Clinical Pharmacokinetics documented CBD inhibition of CYP3A4 at plasma concentrations achievable with typical therapeutic and recreational doses [3]. For context, the FDA label for lemborexant shows that co-administration with moderate CYP3A4 inhibitors can increase lemborexant AUC by approximately 2-fold, and concomitant use with strong CYP3A4 inhibitors raises AUC by up to 4-fold [1].

THC as a Variable CYP3A4 Modulator

THC itself has less consistent CYP3A4 inhibition data than CBD, but preclinical work and some human pharmacokinetic studies suggest it may act as a weak inhibitor at high concentrations [6]. Because commercial cannabis products vary widely in THC-to-CBD ratios, the net CYP3A4 effect of any given product is difficult to predict without knowing its cannabinoid composition.

Next-Day Driving Impairment: The Clearest Clinical Concern

Residual impairment the morning after a dose is one of the most studied risks of lemborexant, and it is directly relevant to cannabis co-use.

What the Driving Simulation Data Show

A Phase 1 randomized, double-blind, crossover study published in Sleep (Moline et al., 2021, N=60) measured on-road and simulator driving performance at 9 hours after bedtime lemborexant doses [5]. Lemborexant 10 mg produced a statistically significant increase in standard deviation of lateral position (SDLP), a validated surrogate for impaired driving, at 9 hours post-dose compared to placebo (P<0.05). The 5 mg dose did not reach statistical significance at the same time point.

Cannabis use would compound these residual effects. THC impairs simulated driving performance in a dose-dependent fashion, with peak impairment roughly 30 to 60 minutes after inhalation and measurable effects persisting for 3 to 4 hours [4]. Edible THC produces a later, longer impairment curve, which may overlap more substantially with morning lemborexant residual levels.

The Practical Warning

Patients using lemborexant should not drive or operate heavy machinery the morning after use if they feel groggy. Adding cannabis, particularly high-THC products or edibles consumed in the evening, extends both the subjective and objective impairment timeline. The National Highway Traffic Safety Administration notes that THC detection in blood does not reliably correlate with current impairment, complicating any legal defense [7].

Can You Drink Alcohol on Dayvigo?

No. The Dayvigo prescribing information states: "Patients should not consume alcohol in combination with DAYVIGO because of the risk of additive CNS depressant effects" [1]. Alcohol is a GABA-A positive allosteric modulator that compounds sedation through a mechanism distinct from, but additive to, orexin blockade. The same SDLP driving-simulation study that evaluated lemborexant alone found that the combination with 0.6 g/kg alcohol produced significantly greater impairment than either substance alone [5].

The alcohol-and-cannabis combination with lemborexant stacks three independent CNS depressant sources simultaneously, which is a pattern that prescribers consistently advise against. Each substance adds impairment on its own; together, the interactions are not always predictable or dose-proportional.

Other Drug Interactions That Affect Lemborexant Exposure

Understanding the cannabis-lemborexant interaction requires knowing where cannabis fits in the broader pharmacokinetic picture of lemborexant.

Strong CYP3A4 Inhibitors

The FDA label contraindicates concurrent use of lemborexant with strong CYP3A4 inhibitors such as itraconazole, clarithromycin, and ritonavir. In a dedicated drug interaction study, ketoconazole (a strong CYP3A4 inhibitor) increased lemborexant AUC by approximately 4-fold [1]. At that level of exposure increase, adverse effects including excessive sedation and respiratory depression risk rise substantially.

Moderate CYP3A4 Inhibitors

Moderate CYP3A4 inhibitors such as fluconazole and diltiazem increase lemborexant AUC by roughly 2-fold. The label recommends limiting the dose to 5 mg when such inhibitors are co-prescribed [1]. CBD-containing cannabis products may produce moderate inhibitory effects, placing them functionally in this category, though head-to-head data comparing CBD to fluconazole in lemborexant PK are not yet available.

CYP3A4 Inducers

Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) can reduce lemborexant AUC by more than 80%, potentially eliminating therapeutic efficacy [1]. Tobacco smoke contains polycyclic aromatic hydrocarbons that induce CYP1A2, a minor metabolic route, and to a lesser degree CYP3A4. Combusted cannabis contains similar compounds. Chronic heavy smokers of cannabis may therefore experience paradoxically lower lemborexant levels through CYP induction, while simultaneously experiencing additive CNS depression through pharmacodynamic mechanisms. These two effects can offset each other unpredictably.

The framework below, developed by the HealthRX medical team, organizes the interaction severity based on cannabis product type and use pattern for clinical discussion with prescribers:

| Cannabis Pattern | Primary Mechanism | Interaction Severity | |---|---|---| | Occasional low-THC flower, evening use | Pharmacodynamic CNS depression | Moderate | | High-THC flower or concentrate, evening use | Pharmacodynamic CNS depression | High | | CBD-dominant product (oral, daily) | CYP3A4 inhibition raising lemborexant AUC | Moderate to High | | THC edible, evening use | Prolonged pharmacodynamic overlap with lemborexant residual | High | | Chronic heavy combusted cannabis | Mixed CYP induction (reducing levels) and CNS depression | Unpredictable |

Prescribers should ask specifically about cannabis product type, cannabinoid content, route of administration, and frequency when assessing this interaction for an individual patient.

Population-Specific Considerations

Older Adults

The FDA label notes that older adults (65 years and above) may be more sensitive to CNS depressant effects of lemborexant [1]. In the Phase 3 SUNRISE-1 trial (N=291), a higher proportion of older participants experienced somnolence compared to younger participants [8]. Cannabis use in older adults has increased substantially over the past decade according to CDC surveillance data; between 2015 and 2018, past-year cannabis use among adults 65 and older rose from 2.4% to 4.2% [9]. This intersection means the clinical population at risk for this interaction is larger than previously assumed.

Patients With Hepatic Impairment

Lemborexant clearance depends on intact hepatic CYP3A4 function. Patients with moderate hepatic impairment show approximately 1.5- to 2-fold higher lemborexant AUC at steady state [1]. CBD and THC are also hepatically metabolized. Co-use in a patient with even mild hepatic dysfunction may produce unexpectedly high lemborexant concentrations.

Patients Taking Benzodiazepines or Z-Drugs

Some patients transition to lemborexant from benzodiazepines or Z-drugs. During a transition period, overlap of the older sedative-hypnotic with lemborexant and cannabis represents a triple CNS depressant combination. Prescribers managing such transitions should taper the legacy agent first before introducing any additional CNS-active substances.

What the Primary Literature Says About Orexin Antagonists and CNS Depressants

The SUNRISE-2 trial (N=949, 12-month duration) tested lemborexant 5 mg and 10 mg against placebo in adults with insomnia disorder [8]. The study excluded participants with active substance use disorders, meaning cannabis-using patients were largely absent from the efficacy and safety database. This gap is a known limitation of key insomnia trials.

A 2023 review in Journal of Clinical Sleep Medicine noted that orexin receptor antagonists as a class carry lower respiratory depression risk than benzodiazepines, but the authors cautioned that "the pharmacodynamic interaction with CNS depressants including cannabinoids has not been characterized in dedicated clinical trials and warrants caution" [10]. That absence of trial data does not mean the interaction is safe; it means the interaction has not been studied well enough to quantify exactly how much impairment to expect.

The European Medicines Agency's assessment report for lemborexant (CHMP assessment) similarly flagged CNS depressant combinations as a class concern and noted that dedicated interaction studies with cannabis were not conducted prior to approval [11].

Practical Guidance for Patients

The decision about cannabis use while taking lemborexant belongs to a conversation with your prescribing clinician. The following points reflect the current evidence base:

• Do not use cannabis on the same evening as lemborexant without explicit clinician approval.
• If you use CBD-containing products daily for another condition, tell your prescriber before starting lemborexant. Your starting dose may need to be 5 mg rather than 10 mg, and your clinician may want to reassess after several weeks.
• Edible cannabis products carry higher interaction risk than inhaled cannabis because their delayed and prolonged absorption curve overlaps more extensively with lemborexant's 17-to-19-hour half-life.
• Do not drive the morning after taking lemborexant plus any cannabis product, regardless of how rested you feel.
• Alcohol adds a third layer of CNS depression. Avoid it on evenings when you take lemborexant.
• Report unexpected morning grogginess, difficulty waking, or memory gaps to your prescriber promptly.

A Note on Disclosing Cannabis Use to Your Prescriber

Many patients do not disclose cannabis use because they fear judgment or legal consequences. In most U.S. States, prescribers cannot report personal cannabis use to law enforcement, and their job is to help you take lemborexant as safely as possible. The SUNRISE trial populations were selected to exclude substance users, so real-world patients who use cannabis represent an unstudied cohort where clinical judgment, not trial data, guides management.

The American Academy of Sleep Medicine (AASM) recommends that clinicians "assess all patients prescribed hypnotic medications for concurrent use of CNS depressants, including cannabinoids, at each clinical encounter" [12]. That recommendation exists because the interaction is real and the consequences, including next-day impairment, fall risk in older adults, and potential respiratory depression in susceptible individuals, are clinically meaningful.

The AASM further states that "insufficient evidence exists to recommend cannabis or cannabinoids as a treatment for insomnia disorder" [12], which is relevant context: cannabis is not a substitute for lemborexant, and the two are not meant to be combined.